Nifedipine versus fosinopril in uninephrectomized diabetic rats

Sharon Anderson, Helmut G. Rennke, Barry M. Brenner

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Antihypertensive agents have been shown to exert inequivalent effects on glomerular injury in experimental renal disease models. To compare the consequences of dissimilar antihypertensive regimens on the development of diabetic glomerulopathy, studies were performed in three groups of uninephrectomized moderately hyperglycemic diabetic rats. One group (DM) received no therapy except insulin. The remaining groups received insulin and either the angiotensin I converting enzyme inhibitor, fosinopril (FOS), or the calcium channel blocker, nifedipine (NIF). Both drugs lowered blood pressure comparably. At four to eight weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (QA) and the glomerular capillary hydraulic pressure (P̄GC). Neither NIF nor FOS affected values for SNGFR or QA. However, while FOS lowered P̄GC and increased Kf, NIF did not affect these parameters. In longer term (8 month) studies, DM rats exhibited progressive albuminuria and glomerular sclerosis. FOS markedly limited development of albuminuria and glomerular injury, but NIF was ineffective in limiting either parameter of glomerular injury. Thus, in contrast to the beneficial effects of converting enzyme inhibitors, chronic calcium channel blockade with nifedipine fails to limit P̄GC or glomerular injury in diabetic rats. These findings lend further support to the concept that different classes of antihypertensive agents are not equally effective in protecting against diabetic glomerulopathy.

Original languageEnglish (US)
Pages (from-to)891-897
Number of pages7
JournalKidney International
Volume41
Issue number4
StatePublished - Apr 1992
Externally publishedYes

Fingerprint

Fosinopril
Nifedipine
Antihypertensive Agents
Albuminuria
Nephrons
Wounds and Injuries
Glomerular Filtration Rate
Insulin
Calcium Channel Blockers
Sclerosis
Enzyme Inhibitors
Calcium Channels
Angiotensin-Converting Enzyme Inhibitors
Blood Pressure
Kidney
Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Nephrology

Cite this

Nifedipine versus fosinopril in uninephrectomized diabetic rats. / Anderson, Sharon; Rennke, Helmut G.; Brenner, Barry M.

In: Kidney International, Vol. 41, No. 4, 04.1992, p. 891-897.

Research output: Contribution to journalArticle

Anderson, S, Rennke, HG & Brenner, BM 1992, 'Nifedipine versus fosinopril in uninephrectomized diabetic rats', Kidney International, vol. 41, no. 4, pp. 891-897.
Anderson, Sharon ; Rennke, Helmut G. ; Brenner, Barry M. / Nifedipine versus fosinopril in uninephrectomized diabetic rats. In: Kidney International. 1992 ; Vol. 41, No. 4. pp. 891-897.
@article{7eab1a04aef34db3a2ee586ecde1fe5d,
title = "Nifedipine versus fosinopril in uninephrectomized diabetic rats",
abstract = "Antihypertensive agents have been shown to exert inequivalent effects on glomerular injury in experimental renal disease models. To compare the consequences of dissimilar antihypertensive regimens on the development of diabetic glomerulopathy, studies were performed in three groups of uninephrectomized moderately hyperglycemic diabetic rats. One group (DM) received no therapy except insulin. The remaining groups received insulin and either the angiotensin I converting enzyme inhibitor, fosinopril (FOS), or the calcium channel blocker, nifedipine (NIF). Both drugs lowered blood pressure comparably. At four to eight weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (QA) and the glomerular capillary hydraulic pressure (P̄GC). Neither NIF nor FOS affected values for SNGFR or QA. However, while FOS lowered P̄GC and increased Kf, NIF did not affect these parameters. In longer term (8 month) studies, DM rats exhibited progressive albuminuria and glomerular sclerosis. FOS markedly limited development of albuminuria and glomerular injury, but NIF was ineffective in limiting either parameter of glomerular injury. Thus, in contrast to the beneficial effects of converting enzyme inhibitors, chronic calcium channel blockade with nifedipine fails to limit P̄GC or glomerular injury in diabetic rats. These findings lend further support to the concept that different classes of antihypertensive agents are not equally effective in protecting against diabetic glomerulopathy.",
author = "Sharon Anderson and Rennke, {Helmut G.} and Brenner, {Barry M.}",
year = "1992",
month = "4",
language = "English (US)",
volume = "41",
pages = "891--897",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Nifedipine versus fosinopril in uninephrectomized diabetic rats

AU - Anderson, Sharon

AU - Rennke, Helmut G.

AU - Brenner, Barry M.

PY - 1992/4

Y1 - 1992/4

N2 - Antihypertensive agents have been shown to exert inequivalent effects on glomerular injury in experimental renal disease models. To compare the consequences of dissimilar antihypertensive regimens on the development of diabetic glomerulopathy, studies were performed in three groups of uninephrectomized moderately hyperglycemic diabetic rats. One group (DM) received no therapy except insulin. The remaining groups received insulin and either the angiotensin I converting enzyme inhibitor, fosinopril (FOS), or the calcium channel blocker, nifedipine (NIF). Both drugs lowered blood pressure comparably. At four to eight weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (QA) and the glomerular capillary hydraulic pressure (P̄GC). Neither NIF nor FOS affected values for SNGFR or QA. However, while FOS lowered P̄GC and increased Kf, NIF did not affect these parameters. In longer term (8 month) studies, DM rats exhibited progressive albuminuria and glomerular sclerosis. FOS markedly limited development of albuminuria and glomerular injury, but NIF was ineffective in limiting either parameter of glomerular injury. Thus, in contrast to the beneficial effects of converting enzyme inhibitors, chronic calcium channel blockade with nifedipine fails to limit P̄GC or glomerular injury in diabetic rats. These findings lend further support to the concept that different classes of antihypertensive agents are not equally effective in protecting against diabetic glomerulopathy.

AB - Antihypertensive agents have been shown to exert inequivalent effects on glomerular injury in experimental renal disease models. To compare the consequences of dissimilar antihypertensive regimens on the development of diabetic glomerulopathy, studies were performed in three groups of uninephrectomized moderately hyperglycemic diabetic rats. One group (DM) received no therapy except insulin. The remaining groups received insulin and either the angiotensin I converting enzyme inhibitor, fosinopril (FOS), or the calcium channel blocker, nifedipine (NIF). Both drugs lowered blood pressure comparably. At four to eight weeks, DM rats exhibited elevation of the single nephron glomerular filtration rate (SNGFR), due to elevations of the glomerular capillary plasma flow rate (QA) and the glomerular capillary hydraulic pressure (P̄GC). Neither NIF nor FOS affected values for SNGFR or QA. However, while FOS lowered P̄GC and increased Kf, NIF did not affect these parameters. In longer term (8 month) studies, DM rats exhibited progressive albuminuria and glomerular sclerosis. FOS markedly limited development of albuminuria and glomerular injury, but NIF was ineffective in limiting either parameter of glomerular injury. Thus, in contrast to the beneficial effects of converting enzyme inhibitors, chronic calcium channel blockade with nifedipine fails to limit P̄GC or glomerular injury in diabetic rats. These findings lend further support to the concept that different classes of antihypertensive agents are not equally effective in protecting against diabetic glomerulopathy.

UR - http://www.scopus.com/inward/record.url?scp=0026550167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026550167&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 891

EP - 897

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 4

ER -